Co-purification of soluble membrane cofactor protein (CD46) and human herpesvirus 6 variant A genome in serum from multiple sclerosis patients

被引:25
作者
Fogdell-Hahn, A
Soldan, SS
Shue, S
Akhyani, N
Refai, H
Ahlqvist, J
Jacobson, S
机构
[1] NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA
[2] George Washington Univ, Inst Biomed Sci, Dept Genet, Washington, DC 20037 USA
[3] Karolinska Hosp, Karolinska Inst, Neurol Sect, S-10401 Stockholm, Sweden
关键词
human herpesvirus 6; CD46; membrane cofactor protein; MCP; multiple sclerosis;
D O I
10.1016/j.virusres.2005.01.005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The association of human herpesvirus 6 (HHV-6) and multiple sclerosis (MS) has been supported by several immunological and molecular studies. Recently, membrane cofactor protein (CD46) has been identified as the cellular receptor for the A and B variants of HHV-6. Elevated levels of soluble CD46 (sCD46) have been reported in the serum and CSF of MS patients. The aim of this study was to investigate a possible correlation between elevated levels of soluble CD46 and the presence of serum HHV-6 DNA in MS patients. An immunoaffinity column comprised of immobilized monoclonal antibodies to CD46 was developed to isolate sCD46 from cell free body fluids of MS patients and controls. After immunoaffinity purification, DNA was extracted from anti-CD46 column eluates and subjected to PCR amplification. Of the 42 MS samples tested, 4 serum samples were HHV-6 positive, 3 of which were typed as HHV-6A. The co-purification of sCD46 and HHV-6 DNA from MS sera indicates that HHV-6 is tightly connected to its receptor, CD46, in the serum of MS patients. Published by Elsevier B.V.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 44 条
[1]   Human herpesvirus-6 (HHV-6) infection in multiple sclerosis: a preliminary report [J].
Ablashi, DV ;
Lapps, W ;
Kaplan, M ;
Whitman, JE ;
Richert, JR ;
Pearson, GR .
MULTIPLE SCLEROSIS, 1998, 4 (06) :490-496
[2]   Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients [J].
Ablashi, DV ;
Eastman, HB ;
Owen, CB ;
Roman, MM ;
Friedman, J ;
Zabriskie, JB ;
Peterson, DL ;
Pearson, GR ;
Whitman, JE .
JOURNAL OF CLINICAL VIROLOGY, 2000, 16 (03) :179-191
[3]   Tissue distribution and variant characterization of human herpesvirus (HHV)-6: Increased prevalence of HHV-6A in patients with multiple sclerosis [J].
Akhyani, N ;
Berti, R ;
Brennan, MB ;
Soldan, SS ;
Eaton, JM ;
McFarland, HF ;
Jacobson, S .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (05) :1321-1325
[4]   Beta-interferon treatment reduces human herpesvirus-6 viral load in multiple sclerosis relapses but not in remission [J].
Alvarez-Lafuente, R ;
De Las Heras, V ;
Bartolomé, M ;
Picazo, JJ ;
Arroyo, R .
EUROPEAN NEUROLOGY, 2004, 52 (02) :87-91
[5]   Increased detection of serum HHV-6 DNA sequences during multiple sclerosis (MS) exacerbations and correlation with parameters of MS disease progression [J].
Berti, R ;
Brennan, MB ;
Soldan, SS ;
Ohayon, JM ;
Casareto, L ;
McFarland, HF ;
Jacobson, S .
JOURNAL OF NEUROVIROLOGY, 2002, 8 (03) :250-256
[6]  
Berti R, 2000, J NEUROVIROL, V6, pS85
[7]   A CD46CD[55-46] chimeric receptor, eight short consensus repeats long, acts as an inhibitor of both CD46 (MCP)- and CD150 (SLAM)-mediated cell-cell fusion induced by CD46-using measles virus [J].
Christiansen, D ;
De Sousa, ER ;
Loveland, B ;
Kyriakou, P ;
Lanteri, M ;
Wild, FT ;
Gerlier, D .
JOURNAL OF GENERAL VIROLOGY, 2002, 83 :1147-1155
[8]   A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro [J].
Christiansen, D ;
Milland, J ;
Thorley, BR ;
McKenzie, IFC ;
Loveland, BE .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (03) :578-585
[9]   Octamerization enables soluble CD46 receptor to neutralize measles virus in vitro and in vivo [J].
Christiansen, D ;
Devaux, P ;
Réveil, B ;
Evlashev, A ;
Horvat, B ;
Lamy, J ;
Rabourdin-Combe, C ;
Cohen, JHM ;
Gerlier, D .
JOURNAL OF VIROLOGY, 2000, 74 (10) :4672-4678
[10]  
Clark DA, 2000, REV MED VIROL, V10, P155, DOI 10.1002/(SICI)1099-1654(200005/06)10:3&lt